Company news

Soligenix, Inc. news in 2024

Soligenix, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL

December 16, 2024

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

December 15, 2024

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

December 1, 2024

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

November 18, 2024

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

November 14, 2024

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

November 13, 2024

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

November 7, 2024

Soligenix Announces Participation at the Spartan Capital Investor Conference

October 28, 2024

Soligenix, Inc. to Present at the 2024 ThinkEquity Conference

October 23, 2024

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

October 21, 2024

Soligenix Invited to Present at Upcoming Investor Conferences

October 15, 2024

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

October 6, 2024

Soligenix Announces Partnership with Sterling Pharma Solutions

October 2, 2024

Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024

September 15, 2024

Soligenix Receives European Patent for Improved Production of Synthetic Hypericin

September 2, 2024

Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results

August 8, 2024

Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

July 8, 2024

Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma

June 24, 2024

A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference

June 13, 2024

Soligenix Announces Reverse Stock Split

May 30, 2024

Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting

May 28, 2024

Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

May 23, 2024

Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split

May 22, 2024

SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference

May 20, 2024

Soligenix Encourages Stockholders to Vote Prior to Annual Meeting

May 19, 2024

Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice

May 15, 2024

Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results

May 9, 2024

Soligenix to Present at Upcoming Conferences

May 5, 2024

Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa

April 24, 2024

Soligenix Announces Pricing of $4.75 Million Public Offering

April 17, 2024

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection

April 14, 2024

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection

April 10, 2024

Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency

April 2, 2024

Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results

March 14, 2024

Soligenix Announces Formation of Behçet's Disease Medical Advisory Board

February 7, 2024

Soligenix to Present at The Microcap Conference

January 24, 2024

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

January 7, 2024

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

January 1, 2024

Decks in 2024